Suchergebnisse - "Jarrett, James"

PubPharm (50)

21

Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study

enthalten in: Clinical drug investigation | 2022

von Ruggeri, M. | Signorini, A. | Caravaggio, S. | +6

22

Evaluation of the diffusion of calcium hydroxide-based medicaments through the dentinal tubules and apical foramen : A mass spectrometry study

enthalten in: Journal of conservative dentistry : JCD | 2021

von Wong, M. | Jarrett, J. | White, A. | +2

23

Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA : insights from the first managed access agreement

enthalten in: Orphanet journal of rare diseases | 2021

von Stevens, B. | Kenny, T. | Thomas, S. | +3

24

Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement

enthalten in: Orphanet journal of rare diseases | 2021

von Stevens, B. | Kenny, T. | Thomas, S. | +3

25

Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy : Payer Perspective in Turkey

enthalten in: Advances in therapy | 2021

von Oksuz, E. | Malhan, S. | Gonen, M. | +8

26

Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey

enthalten in: Advances in therapy | 2021

von Oksuz, E. | Malhan, S. | Gonen, M. | +8

27

Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey

enthalten in: Advances in therapy | 2021

von Oksuz, E. | Malhan, S. | Gonen, M. | +8

28

Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey

enthalten in: Advances in therapy | 2021

von Oksuz, E. | Malhan, S. | Gonen, M. | +8

29

Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA : results from a Managed Access Agreement in England

enthalten in: Orphanet journal of rare diseases | 2021

von Cleary, M. | Davison, J. | Gould, R. | +9

30

Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England

enthalten in: Orphanet journal of rare diseases | 2021

von Cleary, M. | Davison, J. | Gould, R. | +9